Methods for producing and using rejuvenated red blood cells

Patent metadata

Field	Value
Publication number	US-9901599-B2
Application number	US-201514748500-A
Country	US
Kind code	B2
Filing date	Jun 24, 2015
Priority date	Sep 6, 2012
Publication date	Feb 27, 2018
Grant date	Feb 27, 2018

Abstract

Methods for treating blood. The methods comprise obtaining whole blood from a donor, mixing the whole blood with a red blood cell enhancement composition, and incubating the mixture of whole blood and red blood cell enhancement composition. The method can be performed at a time proximate to the time of obtaining blood from the donor, or after the blood has been stored for a period of time. The method rejuvenates red blood cells.

First claim

What is claimed is:

1. A method for restoring a metabolic profile in red blood cells (RBCs), comprising:
obtaining a leukoreduced red blood cell (RBC) component;
mixing the leukoreduced RBC component with an RBC enhancement composition comprising adenine, inosine, pyruvate, phosphate, or a combination thereof;
incubating the mixture of leukoreduced RBC component and RBC enhancement composition for a period of time to form an enhanced leukoreduced RBC component, wherein the leukoreduced RBC component attains a level of 2,3-diphosphoglycerate (2,3-DPG), that is at least about 20% greater than the level of 2,3-DPG in a non-leukoreduced blood component mixed with the RBC enhancement composition and incubated for the same period of time.

2. The method according to claim 1 , wherein the level of nitric oxide in the enhanced leukoreduced RBC component is restored to at least the level of nitric oxide in fresh blood.

3. The method according to claim 1 , wherein the leukoreduced RBC component was stored at 1° C. to about 6° C., or frozen, for 1 to 50 days prior to the obtaining step.

4. The method according to claim 1 , wherein the period of time is less than 1 hour.

5. The method according to claim 1 , wherein the RBC enhancement composition comprises from about 25 g/L to about 30 g/L inosine, from about 0.2 g/L to about 2 g/L adenine, from about 5 g/L to about 15 g/L pyruvate, and from about 17 g/L to about 23 g/L sodium phosphate.

6. The method according to claim 1 , wherein the incubating is at a temperature of from about 25° C. to about 45° C.

7. The method according to claim 1 , wherein incubating includes shaking, swirling, rotating, or agitating the mixture.

8. A method for treating a disorder characterized by reduced tissue oxygenation in a mammalian subject, comprising:
obtaining a leukoreduced red blood cell (RBC) component;
mixing the leukoreduced RBC component with an RBC enhancement composition comprising adenine, inosine, pyruvate, phosphate, or a combination thereof;
incubating the mixture of leukoreduced RBC component and RBC enhancement composition for a period of time to form an enhanced leukoreduced RBC component having a level of adenosine triphosphate (ATP) that is greater than or equal to the level of ATP in fresh blood, and a level of 2,3-diphosphoglycerate (2,3-DPG) that is at least about 20% greater than the level of , 2,3-DPG in in a non-leukoreduced blood component incubated with the RBC enhancement composition for the same period of time, wherein incubating the mixture includes swirling, shaking, rotating, or agitating the mixture; and
administering the enhanced leukoreduced RBC component to the subject.

9. The method according to claim 8 , wherein the leukoreduced RBC component is autologous to the subject.

10. The method according to claim 8 , wherein the RBC enhancement composition comprises from about 25 g/L to about 30 g/L inosine, from about 0.2 g/L to about 2 g/L adenine, from about 5 g/L to about 15 g/L pyruvate, and from about 17 g/L to about 23 g/L sodium phosphate, and has a pH from about 6.7 to about 7.1.

11. The method according to claim 8 , wherein a level of nitric oxide in the enhanced leukoreduced RBC component is restored to at least the level of nitric oxide in fresh blood.

12. The method according to claim 8 , wherein the mixing occurs within 24 hours of drawing blood from a donor of the leukoreduced RBC component.

13. The method according to claim 8 , wherein the leukoreduced RBC component is stored at 1° C. to about 6° C., or frozen, for 1 to 50 days prior to mixing the leukoreduced RBC component with the RBC enhancement composition.

14. The method according to claim 8 , wherein the partial pressure of oxygen gas required to achieve 50% oxygen saturation (P50) in the enhanced leukoreduced RBC component is greater than the P50 in the leukoreduced RBC component.

15. The method according to claim 8 , further comprising washing the enhanced leukoreduced RBC component prior to the step of administering.

16. The method according to claim 8 , wherein the disorder is sepsis, septic shock, Upper Gastrointestinal Bleeding (UGIB), anemia, severe trauma, heart attack or stroke.

17. The method according to claim 8 , wherein the subject is undergoing surgery and is in need of a blood transfusion.

18. The method according to claim 8 , further comprising measuring a level of ATP, 2,3-DPG, nitric oxide, or a combination thereof, in the leukoreduced RBC component prior to the step of mixing or the step of incubating.

19. The method according to claim 8 , further comprising measuring a level of ATP, 2,3-DPG, nitric oxide, or a combination thereof, in the enhanced leukoreduced RBC component during or after the step of incubating.

20. The method according to claim 1 , wherein the partial pressure of oxygen gas required to achieve 50% oxygen saturation (P50) in the enhanced leukoreduced RBC component is greater than the P50 in the leukoreduced RBC component.

21. The method according to claim 1 , further comprising measuring a level of ATP, 2,3-DPG, nitric oxide, or a combination thereof, in the leukoreduced RBC component prior to the step of mixing or the step of incubating.

22. The method according to claim 1 , further comprising measuring a level of ATP, 2,3-DPG, nitric oxide, or a combination thereof, in the enhanced leukoreduced RBC component during or after the step of incubating.

23. A method for treating a disorder characterized by reduced tissue oxygenation in a mammalian subject, comprising:
obtaining a leukoreduced red blood cell (RBC) component;
mixing the leukoreduced RBC component with an RBC enhancement composition comprising adenine, inosine, pyruvate, phosphate, or a combination thereof;
incubating the mixture of leukoreduced RBC component and RBC enhancement composition for a period of about 1 hour to form an enhanced leukoreduced RBC component, wherein the enhanced leukoreduced blood component has a level 2,3-diphosphoglycerate (2,3-DPG) that is at least 20% greater than the level of 2,3-DPG in a non-leukoreduced blood component after mixing with the RBC enhancement composition and incubating the mixture for a period of about 1hour, wherein the mixture is subjected to shaking, swirling, rotating, or agitation during the incubating; and
administering the enhanced leukoreduced RBC component to the subject.

24. The method according to claim 23 , wherein the leukoreduced RBC component is autologous to the subject.

25. The method according to claim 23 , wherein the leukoreduced RBC component was stored at 1° C. to about 6° C., or frozen, for 1 to 50 days before the step of obtaining.

26. The method according to claim 23 , wherein the RBC enhancement composition comprises from about 25 g/L to about 30 g/L inosine, from about 0.2 g/L to about 2 g/L adenine, from about 5 g/L to about 15 g/L pyruvate, and from about 17 g/L to about 23 g/L sodiumphosphate, and has a pH from about 6.7 to about 7.1.

27. The method according to claim 23 , wherein the incubating is at a temperature of from about 25° C. to about 45° C.

Assignees

• Biomet Biologics Llc
• Biomet Biologies Llc

Inventors

• Gray Alan

Classifications

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A01N1/0226

  Human Necessities · mapped topic

• A01N1/00

  Preservation of bodies of humans or animals, or parts thereof · CPC title

• C12N5/0641

  Erythrocytes · CPC title

• A61K31/70

  Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047) · CPC title